Skip to main content
Midas Edge

Prime Medicine, Inc.

For the period ended Sep 30, 2025. Filed Nov 7, 2025.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2025 · Filed Nov 7, 2025

PRME$3.90-9.3%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Condensed Consolidated Statements of Stockholders Equity for the

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

Common Stock · AdditionalPaid-inCapital · Accumulated OtherComprehensiveLosses · AccumulatedDeficit · TotalStockholders’Equity
(in thousands, except share amounts) · Shares · Amount
Balance as of December 31, 2024131,160,842$2$840,358$1$(687,212)$153,149
Stock-based compensation expense——5,681——5,681
Change in unrealized loss on investments, net of tax———(16)—(16)
Net loss————(51,890)(51,890)
Balance as of March 31, 2025131,160,842$2$846,039$(15)$(739,102)$106,924
Exercise of pre-funded warrants3,199,984—————
Issuance of common stock under the employee stock purchase plan133,612—197——197
Stock-based compensation expense——6,325——6,325
Change in unrealized loss on investments, net of tax———5—5
Net loss————(52,591)(52,591)
Balance as of June 30, 2025134,494,438$2$852,561$(10)$(791,693)$60,860
Issuance of common stock from public offering, net of issuance costs of $5.8 million43,700,000—138,380——138,380
Issuance of restricted stock units2,000,000—————
Issuance of common stock upon exercise of stock options115,033—373——373
Stock-based compensation expense——12,747——12,747
Change in unrealized loss on investments, net of tax———43—43
Net loss————(50,582)(50,582)
Balance as of September 30, 2025180,309,471$2$1,004,061$33$(842,275)$161,821

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

Common Stock · AdditionalPaid-inCapital · Accumulated OtherComprehensiveLosses · AccumulatedDeficit · TotalStockholders’Equity
(in thousands, except share amounts) · Shares · Amount
Balance as of December 31, 202397,377,121$2$624,414$(15)$(491,330)$133,071
Issuance of common stock from public offering, net of issuance costs of $8.9 million22,560,001—132,055——132,055
Issuance of pre-funded warrants, net of issuance costs of $1.2 million——18,800——18,800
Issuance of common stock under the employee stock purchase plan74,488—436——436
Issuance of common stock upon exercise of stock options9,664—36——36
Stock-based compensation expense——5,209——5,209
Change in unrealized loss on investments, net of tax———(80)—(80)
Net loss————(45,761)(45,761)
Balance as of March 31, 2024120,021,2742780,950(95)(537,091)243,766
Issuance of common stock upon exercise of stock options9,539—35——35
Stock-based compensation expense——8,091——8,091
Change in unrealized loss on investments, net of tax———24—24
Net loss————(55,327)(55,327)
Balance as of June 30, 2024120,030,813$2$789,076$(71)$(592,418)$196,589
Issue of common stock under the Securities Purchase Agreement to BMS — related party11,006,163—38,081——38,081
Issuance of common stock under the employee stock purchase plan115,021—401——401
Issuance of common stock upon exercise of stock options8,845—32——32
Stock-based compensation expense——6,827——6,827
Change in unrealized loss on investments, net of tax———92—92
Net loss————(52,518)(52,518)
Balance as of September 30, 2024131,160,842$2$834,417$21$(644,936)$189,504
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.